Earnings summaries and quarterly performance for Nuvectis Pharma.
Executive leadership at Nuvectis Pharma.
Board of directors at Nuvectis Pharma.
Research analysts covering Nuvectis Pharma.
Recent press releases and 8-K filings for NVCT.
Nuvectis Pharma Discusses NXP900 Phase 1b Program and Upcoming Milestones
NVCT
New Projects/Investments
Guidance Update
- Nuvectis Pharma held an investor call to discuss the NXP900 phase 1b program for advanced solid tumors, including a combination with osimertinib in non-small cell lung cancer, targeting an estimated 45,000 patients in NSCLC alone.
- The phase 1a study has been completed, demonstrating over 90% Src inhibition in humans at doses starting from 150 mg per day, and the drug appeared well-tolerated without reaching a dose-limiting toxicity.
- The combination segment of the phase 1b program with osimertinib is expected to initiate by year-end.
- Monotherapy data readouts from the phase 1b program are anticipated to begin in the second quarter of 2026 and continue throughout the year, alongside accumulating combination data.
- NXP900 is highlighted as the only oral regimen currently advancing into clinical studies for EGFR resistance, with a unique mechanism of action and no anticipated overlapping toxicities with EGFR or ALK inhibitors.
Dec 2, 2025, 1:00 PM
Nuvectis Pharma Reports Q3 2025 Financial Results and NXP900 Program Updates
NVCT
Earnings
New Projects/Investments
Guidance Update
- Nuvectis Pharma reported a net loss of $7.5 million for the third quarter of 2025, an increase from $4.2 million in the prior year period, primarily due to a $2.0 million milestone achievement expense for NXP900 and $0.7 million related to the clinical drug-drug interaction study.
- Research and development expenses increased to $5.8 million for the three months ended September 30, 2025, up from $2.8 million in the same period of 2024, while general and administrative expenses rose to $2.0 million from $1.5 million.
- The company's cash and cash equivalents stood at $35.4 million as of September 30, 2025, a significant increase from $18.5 million as of December 31, 2024, with a cash runway expected to support operations into Q3 2027.
- Nuvectis initiated the NXP900 Phase 1b program, successfully completed the NXP900 Phase 1a dose escalation study, and finished a clinical drug-drug interaction study for NXP900.
Nov 4, 2025, 1:16 PM
Nuvectis Pharma Reports Third Quarter 2025 Financial Results and Business Highlights
NVCT
Earnings
New Projects/Investments
Guidance Update
- Nuvectis Pharma reported cash and cash equivalents of $35.4 million as of September 30, 2025, an increase from $18.5 million at December 31, 2024, primarily due to a public offering and At-the-Market facility utilization.
- The company's net loss was $7.5 million for the three months ended September 30, 2025, an increase from $4.2 million for the same period in 2024, largely due to a $2.0 million milestone achievement expense and $0.7 million for a clinical drug-drug interaction study.
- Research and development expenses for the third quarter of 2025 were $5.8 million, compared to $2.8 million for the third quarter of 2024.
- The NXP900 Phase 1b program was initiated, with the single agent study underway and the combination portion expected by year-end, following the successful completion of the Phase 1a dose escalation study and a clinical drug-drug interaction study.
- Nuvectis Pharma expects its cash runway to support the company's operations into Q3 2027.
Nov 4, 2025, 1:15 PM
Nuvectis Pharma Reports Third Quarter 2025 Financial Results and NXP900 Clinical Progress
NVCT
Earnings
Guidance Update
New Projects/Investments
- Nuvectis Pharma reported a net loss of $7.5 million for the three months ended September 30, 2025, an increase from $4.2 million in the same period of 2024, primarily due to a $2.0 million milestone achievement expense for NXP900.
- As of September 30, 2025, cash and cash equivalents were $35.4 million, compared to $18.5 million as of December 31, 2024, primarily due to a public offering and At-the-Market facility utilization.
- The company initiated the NXP900 Phase 1b program, with the single-agent study underway and the combination portion expected by year-end, following the successful completion of the Phase 1a dose escalation study.
- Nuvectis Pharma expects its cash runway to support operations into Q3 2027.
Nov 4, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more